Breath Therapeutics Holding BV

About Breath Therapeutics Holding BV

Breath Therapeutics is specializing in advanced and first-in-class inhalation therapies for severe respiratory diseases. For its clinical development, the company is using proprietary drug formulations optimized for inhaled administration with exclusively licenced, high performance nebulizers. Breath Therapeutics is focussing on integrated therapy solutions in the interaction between diagnostic, therapy and eHealth therapy control. The clinical development program is addressing the treatment of Bronchiolitis Obliterans Syndrome (BOS) in patients after lung transplantation. PARI Pharma, a leading nebulizer company, is strategic partner and technology licensee for the BOS development program. Breath Therapeutics is based in Munich and Frankfurt, Germany.
YEAR FOUNDED:
2005
LEADERSHIP:
CEO: Jens Stegemann
CFO: Anne Burger
CSO: Gerhard Boerner
COO: Oliver Denk

9 articles with Breath Therapeutics Holding BV